Verona Pharma PLC Registered Initial Public Offering in the US

 
TIDMVRP 
 
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF 
REGULATION (EU) NO 596/2014 
 
 Verona Pharma Plans to Conduct Registered Initial Public Offering in the U.S. 
 
November 23, 2016, Cardiff - Verona Pharma plc (AIM: VRP) today announced that 
it plans to conduct a registered initial public offering in the United States. 
The number of shares and price of the proposed offering have not yet been 
determined. The proposed offering is expected to commence in the first half of 
2017, after the U.S. Securities and Exchange Commission completes its review 
process of the registration statement relating to the proposed offering and 
subject to market and other conditions. 
 
This press release is being made pursuant to and in accordance with Rule 135 
under the Securities Act of 1933, as amended. This press release does not 
constitute an offer to sell or the solicitation of an offer to buy securities, 
and shall not constitute an offer, solicitation or sale in any jurisdiction in 
which such offer, solicitation or sale would be unlawful prior to registration 
or qualification under the securities laws of that jurisdiction. 
 
Forward Looking Statements 
 
This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of historical 
fact should be considered forward-looking statements, including without 
limitation statements regarding our plans to conduct a registered initial 
public offering in the United States and the timing of the proposed offering. 
 
These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but involve 
known and unknown risks, uncertainties and other important factors that may 
cause our actual results, performance or achievements to be materially 
different from our expectations expressed or implied by the forward-looking 
statements, including, but not limited to, the following: we may determine not 
to conduct a registered initial public offering in the time frame that we 
currently expect or at all, due to a number of potential important factors, 
including conditions in the U.S. capital markets, negative global economic 
conditions, potential negative developments in our clinical trials or research 
programs, other negative developments in our business, or unfavorable 
legislative or regulatory developments. 
 
These and other important factors could cause actual results to differ 
materially from those indicated by the forward-looking statements made in this 
press release. Any such forward-looking statements represent management's 
estimates as of the date of this press release. While we may elect to update 
such forward-looking statements at some point in the future, we disclaim any 
obligation to do so, even if subsequent events cause our views to change. These 
forward-looking statements should not be relied upon as representing our views 
as of any date subsequent to the date of this press release. 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                         Tel: [phone] 
 
Jan-Anders Karlsson, Chief Executive 
Officer 
 
N+1 Singer                                Tel: [phone] 
 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                            Tel: [phone] 
 
Simon Conway / Stephanie Cuthbert / 
Natalie Garland-Collins 
 
 
 
END 
 

(END) Dow Jones Newswires

November 23, 2016 04:17 ET (09:17 GMT)